Wynzora Cream^®️

(calcipotriene and betamethasone dipropionate)
Cream, 0.005%/0.064%

NOW APPROVED IN THE US FOR ADULTS WITH PLAQUE PSORIASIS

Wynzora^®️ Cream is a novel topical treatment for plaque psoriasis in adults uniquely formulated using PAD Technology™. It offers a unique combination of fast and high efficacy, favorable safety profile and is tailormade to optimize treatment convenience in a single product.

Please click here to see more about Wynzora^®️ Cream in the US and mode of action involving the hallmark IL-23 and IL-17 immune axis and TNF-α expression, leading to epidermal hyperproliferation inflammation and itch.

Please click here to obtain the FDA-approved Full Prescribing Information for the US.

Please click here to obtain a summary of product characteristics for countries in EU.